von Willebrand Factor Inhibition Improves Endothelial Function in Patients with Stable Angina

  • Olivier Muller
  • Jozef Bartunek
  • Michalis Hamilos
  • Catalina Trana Berza
  • Fabio Mangiacapra
  • Argyrios Ntalianis
  • Kristof Vercruysse
  • Christian Duby
  • William Wijns
  • Bernard De Bruyne
  • Guy R. Heyndrickx
  • Marc Vanderheyden
  • Josefin-Beate Holz
  • Emanuele Barbato
Article

Abstract

ALX-0081 is a novel nano-antibody inhibiting von Willebrand factor (vWF). We evaluated whether direct inhibition of vWF by ALX-0081 improves endothelial function. Stable patients (pts, n = 55) with single vessel disease undergoing percutaneous coronary intervention (PCI) were randomized to ALX-0081 (n = 38) or placebo (n = 17). vWF inhibition was assessed by vWF antigen level (vWF:Ag) and activity by ristocetin test (vWF:RiCo). Endothelial function was assessed before (BL), 6 h and 24 h after PCI by: (a) endothelial peripheral arterial tonometry (Endoscore); (b) endothelial microparticles (EMPs) by flow cytometry. vWF:Ag and vWF:RiCo decreased within 1 h from ALX-0081. In the placebo group, no significant Endoscore changes occurred from BL to 24 h. In ALX-0081 group, Endoscore increased from BL to 24 h (p = 0.014). A decrease in EMPs was observed after ALX-0081 (p < 0.01), while no changes occurred in placebo pts. An inhibition of vWF with ALX-0081 significantly improves peripheral endothelial function.

Keywords

von Willebrand factor Nano-antibody Endothelial function Coronary artery disease PCI 

References

  1. 1.
    Reriani, M. K., Lerman, L. O., & Lerman, A. (2010). Endothelial function as a functional expression of cardiovascular risk factors. Biomarkers in Medicine, 4(3), 351–360.PubMedCrossRefGoogle Scholar
  2. 2.
    Lembo, G., Morisco, C., Lanni, F., Barbato, E., Vecchione, C., Fratta, L., & Trimarco, B. (1998). Systemic hypertension and coronary artery disease: the link. The American Journal of Cardiology, 82, 2H–7H.PubMedCrossRefGoogle Scholar
  3. 3.
    Barbato, E., Bartunek, J., Wyffels, E., Wijns, W., Heyndrickx, G. R., & De Bruyne, B. (2003). Effects of intravenous dobutamine on coronary vasomotion in humans. Journal of the American College of Cardiology, 42, 1596–1601.PubMedCrossRefGoogle Scholar
  4. 4.
    Barbato, E., Piscione, F., Bartunek, J., Galasso, G., Cirillo, P. L., De Luca, G., Iaccarino, G., De Bruyne, B., Chiariello, M., & Wijns, W. (2005). Role of beta2 adrenergic receptors in human atherosclerotic coronary arteries. Circulation, 111(3), 288–294.PubMedCrossRefGoogle Scholar
  5. 5.
    Bonetti, P. O., Lerman, L. O., & Lerman, A. (2003). Endothelial dysfunction: a marker of atherosclerotic risk. Arteriosclerosis, Thrombosis, and Vascular Biology, 23(2), 168–175.PubMedCrossRefGoogle Scholar
  6. 6.
    Brevetti, G., Piscione, F., Cirillo, P., Galasso, G., Schiano, V., Barbato, E., Scopacasa, F., & Chiariello, M. (2008). In concomitant coronary and peripheral arterial disease, inflammation of the affected limbs predicts coronary artery endothelial dysfunction. Atherosclerosis, 201(2), 440–446.PubMedCrossRefGoogle Scholar
  7. 7.
    Treasure, C. B., Klein, J. L., Weintraub, W. S., Talley, J. D., Stillabower, M. E., Kosinski, A. S., Zhang, J., Boccuzzi, S. J., Cedarholm, J. C., & Alexander, R. W. (1995). Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. The New England Journal of Medicine, 332(8), 481–487.PubMedCrossRefGoogle Scholar
  8. 8.
    Ridker, P. M., Danielson, E., Fonseca, F. A., Genest, J., Gotto, A. M., Jr., Kastelein, J. J., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., Nordestgaard, B. G., Shepherd, J., Willerson, J. T., & Glynn, R. J. (2008). Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. The New England Journal of Medicine, 359(21), 2195–2207.PubMedCrossRefGoogle Scholar
  9. 9.
    Hambrecht, R., Wolf, A., Gielen, S., Linke, A., Hofer, J., Erbs, S., Schoene, N., & Schuler, G. (2000). Effect of exercise on coronary endothelial function in patients with coronary artery disease. The New England Journal of Medicine, 342(7), 454–460.PubMedCrossRefGoogle Scholar
  10. 10.
    Hamilos, M., Sarma, J., Ostojic, M., Cuisset, T., Sarno, G., Melikian, N., Ntalianis, A., Muller, O., Barbato, E., Beleslin, B., Sagic, D., De Bruyne, B., Bartunek, J., & Wijns, W. (2008). Interference of drug-eluting stents with endothelium-dependent coronary vasomotion: evidence for device-specific responses. Circulation Cardiovascular Interventions, 1(3), 193–200.PubMedCrossRefGoogle Scholar
  11. 11.
    Vischer, U. M. (2006). von Willebrand factor, endothelial dysfunction, and cardiovascular disease. Journal of Thrombosis and Haemostasis, 4(6), 1186–1193.PubMedCrossRefGoogle Scholar
  12. 12.
    Muller, O., Hamilos, M., Bartunek, J., Ulrichts, H., Mangiacapra, F., Holz, JB., et al. Relation of endothelial function to residual platelet reactivity after clopidogrel in patients with stable angina pectoris undergoing percutaneous coronary intervention. American Journal of Cardiology, 105(3), 333–338Google Scholar
  13. 13.
    Bickel, C., Rupprecht, H. J., Blankenberg, S., Espinola-Klein, C., Rippin, G., Hafner, G., Lotz, J., Prellwitz, W., & Meyer, J. (2002). Influence of HMG-CoA reductase inhibitors on markers of coagulation, systemic inflammation and soluble cell adhesion. International Journal of Cardiology, 82(1), 25–31.PubMedCrossRefGoogle Scholar
  14. 14.
    Companion paper from Bartunek, J., & Holtz J. (2013). Novel antiplatelet agents: ALX-0081, a nanobody directed toward von Willebrand factor. Journal Cardiovascular Translational Research Google Scholar
  15. 15.
    Cuisset, T., Hamilos, M., Melikian, N., Wyffels, E., Sarma, J., Sarno, G., Barbato, E., Bartunek, J., Wijns, W., & De Bruyne, B. (2008). Direct stenting for stable angina pectoris is associated with reduced periprocedural microcirculatory injury compared with stenting after pre-dilation. Journal of the American College of Cardiology, 51(11), 1060–1065.PubMedCrossRefGoogle Scholar
  16. 16.
    Hamburg, N. M., Keyes, M. J., Larson, M. G., Vasan, R. S., Schnabel, R., Pryde, M. M., Mitchell, G. F., Sheffy, J., Vita, J. A., & Benjamin, E. J. (2008). Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham heart study. Circulation, 117(19), 2467–2474.PubMedCrossRefGoogle Scholar
  17. 17.
    Cuisset, T., Hamilos, M., Sarma, J., Sarno, G., Wyffels, E., Vanderheyden, M., Barbato, E., Bartunek, J., De Bruyne, B., & Wijns, W. (2008). Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris. The American Journal of Cardiology, 101(12), 1700–1703.PubMedCrossRefGoogle Scholar
  18. 18.
    Mangiacapra, F., De Bruyne, B., Muller, O., Trana, C., Ntalianis, A., Bartunek, J., Heyndrickx, G., Di Sciascio, G., Wijns, W., & Barbato, E. (2010). High residual platelet reactivity after clopidogrel: extent of coronary atherosclerosis and periprocedural myocardial infarction in patients with stable angina undergoing percutaneous coronary intervention. Journal American College of Cardiology Cardiovasc Intervention, 3(1), 35–40.Google Scholar
  19. 19.
    Hamilos, M., Muller, O., Ntalianis, A., Trana, C., Bartunek, J., Sarno, G., Mangiacapra, F., Dierickx, K., Meeus, P., Cuisset, T., De Bruyne, B., Wijns, W., & Barbato, E. (2011). Relationship between peripheral arterial reactive hyperemia and residual platelet reactivity after 600 mg clopidogrel. Journal of Thrombosis and Thrombolysis, 32(1), 64–71.PubMedCrossRefGoogle Scholar
  20. 20.
    Ulrichts, H., Silence, K., Schoolmeester, A., de Jaegere, P., Rossenu, S., Roodt, J., Priem, S., Lauwereys, M., Casteels, P., Van Bockstaele, F., Verschueren, K., Stanssens, P., Baumeister, J., & Holz, J. B. (2011). Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs. Blood, 118(3), 757–765.PubMedCrossRefGoogle Scholar
  21. 21.
    Deanfield, J. E., Halcox, J. P., & Rabelink, T. J. (2007). Endothelial function and dysfunction: testing and clinical relevance. Circulation, 115(10), 1285–1295.PubMedGoogle Scholar
  22. 22.
    Hansson, G. K. (2005). Inflammation, atherosclerosis, and coronary artery disease. The New England Journal of Medicine, 352(16), 1685–1695.PubMedCrossRefGoogle Scholar
  23. 23.
    Jilma, B., Pernerstorfer, T., Dirnberger, E., Stohlawetz, P., Schmetterer, L., Singer, E. A., Grasseli, U., Eichler, H. G., & Kapiotis, S. (1998). Effects of histamine and nitric oxide synthase inhibition on plasma levels of von Willebrand factor antigen. The Journal of Laboratory and Clinical Medicine, 131(2), 151–156.PubMedCrossRefGoogle Scholar
  24. 24.
    Pernerstorfer, T., Stohlawetz, P., Kapiotis, S., Eichler, H. G., & Jilma, B. (2000). Partial inhibition of nitric oxide synthase primes the stimulated pathway of vWF-secretion in man. Atherosclerosis, 148(1), 43–47.PubMedCrossRefGoogle Scholar
  25. 25.
    Golino, P., Buja, L. M., Ashton, J. H., Kulkarni, P., Taylor, A., & Willerson, J. T. (1988). Effect of thromboxane and serotonin receptor antagonists on intracoronary platelet deposition in dogs with experimentally stenosed coronary arteries. Circulation, 78(3), 701–711.PubMedCrossRefGoogle Scholar
  26. 26.
    Yao, S. K., Ober, J. C., McNatt, J., Benedict, C. R., Rosolowsky, M., Anderson, H. V., Cui, K., Maffrand, J. P., Campbell, W. B., & Buja, L. M. (1992). ADP plays an important role in mediating platelet aggregation and cyclic flow variations in vivo in stenosed and endothelium-injured canine coronary arteries. Circulation Research, 70(1), 39–48.PubMedCrossRefGoogle Scholar
  27. 27.
    Bush, L. R., Campbell, W. B., Buja, L. M., Tilton, G. D., & Willerson, J. T. (1984). Effects of the selective thromboxane synthetase inhibitor dazoxiben on variations in cyclic blood flow in stenosed canine coronary arteries. Circulation, 69(6), 1161–1170.PubMedCrossRefGoogle Scholar
  28. 28.
    McGhie, A. I., McNatt, J., Ezov, N., Cui, K., Mower, L. K., Hagay, Y., Buja, L. M., Garfinkel, L. I., Gorecki, M., & Willerson, J. T. (1994). Abolition of cyclic flow variations in stenosed, endothelium-injured coronary arteries in nonhuman primates with a peptide fragment (VCL) derived from human plasma von Willebrand factor-glycoprotein Ib binding domain. Circulation, 90(6), 2976–2981.PubMedCrossRefGoogle Scholar
  29. 29.
    Bonetti, P. O., Barsness, G. W., Keelan, P. C., Schnell, T. I., Pumper, G. M., Kuvin, J. T., Schnall, R. P., Holmes, D. R., Higano, S. T., & Lerman, A. (2003). Enhanced external counterpulsation improves endothelial function in patients with symptomatic coronary artery disease. Journal of the American College of Cardiology, 41(10), 1761–1768.PubMedCrossRefGoogle Scholar
  30. 30.
    Kuvin, J. T., Patel, A. R., Sliney, K. A., Pandian, N. G., Sheffy, J., Schnall, R. P., Karas, R. H., & Udelson, J. E. (2003). Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude. American Heart Journal, 146(1), 168–174.PubMedCrossRefGoogle Scholar
  31. 31.
    Krantz, D. S., Santiago, H. T., Kop, W. J., Bairey Merz, C. N., Rozanski, A., & Gottdiener, J. S. (1999). Prognostic value of mental stress testing in coronary artery disease. American Journal of Cardiology, 84(11), 1292–1297.PubMedCrossRefGoogle Scholar
  32. 32.
    Lavie, P., Shlitner, A., Sheffy, J., & Schnall, R. P. (2000). Peripheral arterial tonometry: a novel and sensitive non-invasive monitor of brief arousals during sleep. The Israel Medical Association Journal, 2(3), 246–247.PubMedGoogle Scholar
  33. 33.
    Bonetti, P. O., Pumper, G. M., Higano, S. T., Holmes, D. R., Jr., Kuvin, J. T., & Lerman, A. (2004). Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. Journal of the American College of Cardiology, 44(11), 2137–2141.PubMedCrossRefGoogle Scholar
  34. 34.
    Rubinshtein, R., Kuvin, J. T., Soffler, M., Lennon, R. J., Lavi, S., Nelson, R. E., Pumper, G. M., Lerman, L. O., & Lerman, A. (2010). Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events. European Heart Journal, 31(9), 1142–1148.PubMedCrossRefGoogle Scholar
  35. 35.
    Woywodt, A., Bahlmann, F. H., De Groot, K., Haller, H., & Haubitz, M. (2002). Circulating endothelial cells: life, death, detachment and repair of the endothelial cell layer. Nephrology, Dialysis, Transplantation, 17(10), 1728–1730.PubMedCrossRefGoogle Scholar
  36. 36.
    Mallat, Z., Benamer, H., Hugel, B., Benessiano, J., Steg, P. G., Freyssinet, J. M., & Tedgui, A. (2000). Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation, 101(8), 841–843.PubMedCrossRefGoogle Scholar
  37. 37.
    Hamilos, H., Sarma, J., Ostojic, M., Cuisset, T., Sarno, G., Melikian, N., Ntalianis, A., Muller, O., Barbato, E., Belesin, B., Sagic, D., De Bruyne, B., Bartunek, J., & Wijns, W. (2008). Interference of drug-eluting stents with endothelium-dependant coronary vasomotion. Circulation: Cardiovascular Intervention, 1, 193–200.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  • Olivier Muller
    • 1
  • Jozef Bartunek
    • 1
  • Michalis Hamilos
    • 1
  • Catalina Trana Berza
    • 1
  • Fabio Mangiacapra
    • 1
  • Argyrios Ntalianis
    • 1
  • Kristof Vercruysse
    • 2
  • Christian Duby
    • 2
  • William Wijns
    • 1
  • Bernard De Bruyne
    • 1
  • Guy R. Heyndrickx
    • 1
  • Marc Vanderheyden
    • 1
  • Josefin-Beate Holz
    • 2
  • Emanuele Barbato
    • 1
  1. 1.Cardiovascular Center Aalst OLV ClinicB-9300 AalstBelgium
  2. 2.Ablynx NVZwijnaardeBelgium

Personalised recommendations